---
title: "Cumberland Pharma | 8-K: FY2025 Q3 Revenue: USD 8.292 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264296735.md"
datetime: "2025-11-04T22:16:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264296735.md)
  - [en](https://longbridge.com/en/news/264296735.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264296735.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/264296735.md) | [繁體中文](https://longbridge.com/zh-HK/news/264296735.md)


# Cumberland Pharma | 8-K: FY2025 Q3 Revenue: USD 8.292 M

Revenue: As of FY2025 Q3, the actual value is USD 8.292 M.

EPS: As of FY2025 Q3, the actual value is USD -0.13.

EBIT: As of FY2025 Q3, the actual value is USD -1.987 M.

### Segment Revenue

-   **Third Quarter 2025**: Total net revenue was $8.3 million, with contributions from Kristalose® ($1.2 million), Sancuso® ($3.2 million), Vibativ® ($2.6 million), and Caldolor® ($0.9 million).
-   **Year-to-date 2025**: Total net revenue was $30.8 million, with Kristalose® contributing $7.4 million, Sancuso® $8.6 million, Vibativ® $6.7 million, and Caldolor® $3.8 million.

### Operational Metrics

-   **Operating Expenses**: $10.3 million for the third quarter and $32.3 million year-to-date 2025.
-   **Net Income (Loss)**: - $1.9 million for the third quarter and - $1.4 million year-to-date 2025.
-   **Adjusted Earnings**: - $0.8 million, or - $0.06 per share for the third quarter; $1.9 million, or $0.13 per diluted share year-to-date 2025.

### Cash Flow

-   **Net Cash Provided by Operating Activities**: $4.9 million.
-   **Net Cash Used in Investing Activities**: - $1.6 million.
-   **Net Cash Used in Financing Activities**: - $6.1 million.

### Balance Sheet (as of September 30, 2025)

-   **Total Assets**: $66 million.
-   **Cash and Cash Equivalents**: $15 million.
-   **Liabilities**: $40 million.
-   **Shareholders’ Equity**: $26 million.

### Outlook / Guidance

Cumberland Pharmaceuticals Inc. is focused on providing unique products to improve patient care and is encouraged by the progress of its development programs for orphan patient populations. The company is optimistic about the potential value creation from its new commercial product, Talicia, and its international agreements for Vibativ and ibuprofen injection products.

### Related Stocks

- [Cumberland Pharmaceuticals Inc. (CPIX.US)](https://longbridge.com/en/quote/CPIX.US.md)

## Related News & Research

- [Did Potential Jail Staffing Efficiencies From SUBLOCADE® Just Shift Indivior Pharmaceuticals' (INDV) Investment Narrative?](https://longbridge.com/en/news/281502261.md)
- [Aurobindo Pharma to consider buyback of equity shares](https://longbridge.com/en/news/281214424.md)
- [Tensions Cloud a Spring Market That Was Just Finding Its Footing, According to Realtor.com® March Housing Report | NWS Stock News](https://longbridge.com/en/news/281344252.md)
- [Ascendis Pharma Expands Share Capital Following March 30 Warrant Exercises](https://longbridge.com/en/news/281085163.md)
- [Protiviti Earns Fortune 100 Best Companies to Work For® Recognition for 12th Consecutive Year | RHI Stock News](https://longbridge.com/en/news/281380757.md)